Vanda Pharmaceuticals (VNDA) Depreciation Expense (2017 - 2026)
Vanda Pharmaceuticals recorded quarterly Depreciation Expense of $273000.0 in Q1 2026, down 10.2% quarter-over-quarter from $304000.0 in Q4 2025, and up 18.18% year-over-year from $231000.0 in Q1 2025.
Vanda Pharmaceuticals' Depreciation Expense history runs 10 years deep, the most recent figure standing at $273000.0 for Q1 2026.
- In Q1 2026, Depreciation Expense rose 18.18% year-over-year to $273000.0; the TTM figure through Mar 2026 stood at $1.1 million (up 23.78% YoY), while the FY2025 annual figure was $1.1 million, up 22.56% from the prior year.
- Depreciation Expense came in at $273000.0 for Q1 2026 at Vanda Pharmaceuticals, down from $304000.0 in the prior quarter.
- In the past five years, Depreciation Expense ranged from a high of $323000.0 in Q1 2022 to a low of $200000.0 in Q3 2023.
- A 5-year average of $258588.2 and a median of $267000.0 in 2022 frame the typical range for Depreciation Expense.
- Across the five-year window, Depreciation Expense sank 33.11% in 2023 and jumped 39.35% in 2025, its largest moves.
- Vanda Pharmaceuticals' Depreciation Expense stood at $267000.0 in 2022, then retreated by 23.22% to $205000.0 in 2023, then rose by 27.8% to $262000.0 in 2024, then grew by 16.03% to $304000.0 in 2025, then dropped by 10.2% to $273000.0 in 2026.
- According to Business Quant data, Depreciation Expense over the past three periods registered $273000.0, $304000.0, and $301000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | 273,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 273,000.00 |
| Dec 31, 2025 | 304,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 267,000.00 |
| Mar 31, 2025 | 231,000.00 |
| Dec 31, 2024 | 262,000.00 |
| Sep 30, 2024 | 216,000.00 |
| Jun 30, 2024 | 216,000.00 |
| Mar 31, 2024 | 206,000.00 |
| Dec 31, 2023 | 205,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 224,000.00 |
| Mar 31, 2023 | 291,000.00 |
| Dec 31, 2022 | 267,000.00 |
| Sep 30, 2022 | 299,000.00 |
| Jun 30, 2022 | 311,000.00 |
| Mar 31, 2022 | 323,000.00 |
| Dec 31, 2021 | 374,000.00 |
| Sep 30, 2021 | 338,000.00 |
| Jun 30, 2021 | 343,000.00 |
| Mar 31, 2021 | 345,000.00 |
| Dec 31, 2020 | 357,000.00 |
| Sep 30, 2020 | 349,000.00 |
| Jun 30, 2020 | 343,000.00 |
| Mar 31, 2020 | 351,000.00 |
| Dec 31, 2019 | 378,000.00 |
| Sep 30, 2019 | 350,000.00 |
| Jun 30, 2019 | 340,000.00 |
| Mar 31, 2019 | 332,000.00 |
| Dec 31, 2018 | 372,000.00 |
| Sep 30, 2018 | 351,000.00 |
| Jun 30, 2018 | 357,000.00 |
| Mar 31, 2018 | 349,000.00 |
| Dec 31, 2017 | 305,000.00 |
| Sep 30, 2017 | 342,000.00 |